We’re thrilled to share that Advarra has been selected as the preferred Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) partner for Sarah Cannon Research Institute (SCRI) in support of their late-stage oncology trials.
SCRI, a leading oncology research organizations conducting community-based clinical trials, has contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. The institute’s expansive research network includes more than 1,300 physicians enrolling patients in clinical trials across nearly 250 locations in more than 20 states.
This partnership is designed to advance oncology research while ensuring all studies meet and exceed rigorous ethical and regulatory standards. Advarra’s extensive IRB and IBC infrastructure and robust meeting schedule provide greater flexibility and operational efficiency—streamlining study activation and supporting compliant, high-quality execution. With more than a decade of using Advarra’s Clinical Conductor CTMS to manage trial operations organization-wide, SCRI’s choice to designate Advarra as its preferred IRB and IBC provider is a natural and seamless progression of their longstanding relationship.
“Advarra has long been the leading IRB for oncology research, overseeing more than twice as many oncology trials as any other IRB, spanning all phases and some of the most complex studies in cell and gene therapy, immuno-oncology, and beyond,” said Lauri Carlile, Chief Research Services Officer at Advarra. “Our collaboration with Sarah Cannon Research Institute advances our shared mission to accelerate clinical trials and bring innovative treatments to patients faster, while safeguarding those who make it possible.”
With decades of experience, robust processes, hands-on customer support, and a commitment to regulatory compliance and the highest ethical standards, Advarra provides the expertise and efficiency needed to support large-scale research. This specialization is evident in our work with some of the nation’s most advanced cancer centers and research programs.
Advarra provides oversight for 100% of National Cancer Institute (NCI)-designated cancer center studies that rely on commercial IRBs. Our network of more than 400 oncology-focused board members and reviewers brings specialized expertise across a wide range of oncology research, from pediatrics and targeted therapies to cell and gene therapies, medical devices, and complex protocol designs. Additionally, compared to other IRBs, we conduct seven times more meetings with oncology representation per week. This extensive experience enables us to deliver comprehensive ethical oversight for cutting-edge research across all oncology indications. Advarra is also the leading provider of Clinical Trial Management Systems (CTMSs), including OnCore and Clinical Conductor, for research sites and institutions. Our CTMSs are used by over 80% of NCI-Designated Cancer Centers, more than 90 of the top 125 Academic Medical Centers, and over 300 site networks to manage their trial operations
As the landscape of cancer research evolves, collaborations like this partnership with SCRI are vital in driving innovation and ensuring patient safety. We’re proud to play a key role in shaping the future of cancer care and remain dedicated to supporting the clinical trials that make these advancements a reality.
To learn more about Advarra’s IRB and how it can serve your oncology trial visit: https://www.advarra.com/review-services/institutional-review-board-services/